'Can't say no': Kite Pharma taps Frank Neumann as new head of clinical development
Kite Pharma hit a major landmark in July when it got a second FDA OK, creating the first commercial CAR-T portfolio. But a biotech’s work is never done. Now it’s time to expand — and the Gilead subsidiary has tapped a new global head of clinical development to lead the charge.
“Kite was always kind of on the horizon as the… dream job come true,” Frank Neumann told Endpoints News. “This is a position (where) if you’re interested in cell therapy, if you’re interested in making a big impact on patients’ lives, you just can’t say no.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.